Humacyte's Bioengineered Blood Vessel Shows Superiority in Phase 3, Keeping Dialysis Patients Catheter-Free 3 Months Longer
HUMA sits 97% above its 52-week low of $0.547.
Summary
Humacyte presented detailed positive Phase 3 results for its ATEV bioengineered blood vessel, demonstrating superior performance over the standard of care for women on dialysis. Patients receiving ATEV averaged three more months without a dialysis catheter and experienced significantly fewer infections. This follows the company's June 10th announcement of meeting the primary endpoint and is crucial for a company that recently issued a going concern warning. The strong data supports a supplemental BLA filing with the FDA later this year. An investor event is scheduled for today, June 15th, at 5:00 p.m. ET.
At the time of this announcement, HUMA was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $234.2M. The 52-week trading range was $0.55 to $2.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.